Leveraging Advanced Omics to Uncover Fibrotic Pathomechanisms & Identify Novel Approaches, Evaluate Biomarker Strategy, & Assess Antifibrotics in an Evolving Landscape to Cement Candidate Confidence
Since Madrigal’s Resmetirom secured the first-ever MASH approval in 2024, 2025 went on to deliver a wave of positive antifibrotic advances. United Therapeutics’ Phase 3 win, the FDA’s review of non-invasive endpoints for MASH, Boehringer’s Phase 3 IPF readout, Stanford’s TGF-β breakthroughs in cardiovascular fibrosis, and more than $3B in deals from Lilly and GSK collectively underscored how critical it had become for developers to demonstrate true differentiation-whether through novel targets, innovative biomarker strategies, or pan-fibrotic mechanisms.
These shared challenges were tackled head-on by 80+ leaders from Pfizer, Novartis, Gilead Sciences, and pioneering biotechs at the Antifibrotic Drug Development Summit - he only cross-fibrosis industry meeting uniting discovery through Phase 2 across IPF, MASH, kidney, cardiac, and systemic sclerosis fibrosis.
This conference allowed me to get up to date with the large (and growing) amount of effort in the field of fibrosis. There's no other way to get so much information in 2-3 days. Very informative.
Neuraly
Very dynamic interactions and vibrant discussions excellent with experts from the field.
Development Center for Biotechnology
Excellently organized, the workshops and conference went smoothly and offered ample opportunity to get in contact with colleagues and for networking; it is not a question of one single highlight, the overall concept worked out nicely.
Vivoryon Therapeutics
Download the 2025 Full Event Guide:
- 80+ industry leaders from top pharma, biotech, and academic organisations
- Actionable strategies across IPF, MASH, kidney, cardiac, and gut fibrosis, all in one place
- Exclusive data from recent approvals and Phase 2 successes
- Cutting-edge science including spatial omics, ADCs, and collagen-targeted PET imaging with pioneers
- 8+ hours of tailored networking opportunities
Official Partners
Attending Companies Include
Explore Related Events
Explore the 2025 Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.